# LWBP

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lwbp

- Headquarters: Shanghai, China
- Website: http://lwbpsh.com
- Latest round: Series B (Oct 27, 2025)
- Investors on record: 5

## About

Founded in 2012 and based in Shanghai, China, Shanghai Longwood Biopharmaceuticals Co., Ltd., trading as LWBP specializes in oncology drug development. In October 2025, LWBP raised Series B funding from new investors Xiamen C&D Group, Wuxi Huading Capital, Qiming Venture Partners, Chuchang Fund and Shanghai STVC Group.
LWBP specializes in developing innovative pharmaceuticals that address unmet clinical needs, with a focus on autoimmune diseases, tumor immunotherapy, and antiviral therapies. Its core product, LW231, is a Class 1 new drug designed for the complete cure of hepatitis B and is currently in Phase Ib/II clinical trials. LWBP engages in medical translation and commercialization through partnerships and licensing agreements, extending its market reach beyond China.
Revenue generation is structured through partnerships and licensing agreements with pharmaceutical companies and healthcare providers, facilitating direct procurement of treatments by healthcare institutions. The company aims to provide competitive and affordable solutions for a broad market segment.

## Funding rounds

- Series B, Oct 27, 2025 — Qiming Venture Partners, Shanghai STVC Group, Xiamen C&D Group, Wuxi Huading Venture Capital, Chuchang Fund

## Investors

- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series B
- Shanghai STVC Group (https://capitalatlas.ai/funds/shanghai-stvc-group) — Series B
- Xiamen C&D Group — Series B
- Wuxi Huading Venture Capital (https://capitalatlas.ai/funds/wuxi-huading-venture-capital) — Series B
- Chuchang Fund (https://capitalatlas.ai/funds/chuchang-fund) — Series B